Metabolomics and bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 5, 2011, Pages 558-561

  Hyndman, Matthew E ^a   Mullins, Jeffrey K ^a   Bivalacqua, Trinity J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Bladder cancer; Cystoscopy; Cytology; Diagnosis; HPLC; Metabolomics; NMR; Review; Urine

Indexed keywords

ALANINE; CHOLESTEROL; CITRIC ACID; GLUCOSE; GLYCEROPHOSPHORYLCHOLINE; LACTIC ACID; PHOSPHORYLCHOLINE;

BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); DIAGNOSTIC VALUE; GAS CHROMATOGRAPHY; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; LACTATE BLOOD LEVEL; MASS SPECTROMETRY; METABOLOMICS; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; TIME OF FLIGHT MASS SPECTROMETRY; TISSUE LEVEL; URINALYSIS;

HUMANS; METABOLOMICS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 80052918426     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.05.014     Document Type: Review

References (29)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Messing E.M., Young T.B., Hunt V.B., et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening vs. those with standard clinical presentations. Urology 1995, 45:387-396. Discussion 96-7.
3. Sciarra A., De Matteis A., Mariotti G., et al. Histopathologic aspects of transitional cell carcinoma of the bladder: Analysis of 20 years experience. Int J Urol 2004, 11:467-475.
4. Lutzeyer W., Rubben H., Dahm H. Prognostic parameters in superficial bladder cancer: An analysis of 315 cases. J Urol 1982, 127:250-252.
5. Wang J.H., Byun J., Pennathur S. Analytical approaches to metabolomics and applications to systems biology. Semin Nephrol 2010, 30:500-511.
6. Lindon J.C., Nicholson J.K. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu Rev Anal Chem (Palo Alto, CA) 2008, 1:45-69.
7. Roberts M.J., Schirra H.J., Lavin M.F., et al. Metabolomics: A novel approach to early and noninvasive prostate cancer detection. Korean J Urol 2011, 52:79-89.
8. Slupsky C.M., Steed H., Wells T.H., et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 2010, 16:5835-5841.
9. Chan E.C., Koh P.K., Mal M., et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 2009, 8:352-361.
10. Wu H., Xue R., Dong L., et al. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta 2009, 648:98-104.
11. Sreekumar A., Poisson L.M., Rajendiran T.M., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
12. Fan Y., Murphy T.B., Byrne J.C., et al. Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer. J Proteome Res 2011, 10:1361-1373.
13. Sirven J.I. CSI: Epilepsy. Epilepsy Behav 2010, 17:307-308.
14. Sitter B., Bathen T.F., Singstad T.E., et al. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed 2010, 23:424-431.
15. Glunde K., Jie C., Bhujwalla Z.M. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004, 64:4270-4276.
16. Bathen T.F., Jensen L.R., Sitter B., et al. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 2007, 104:181-189.
17. Swanson M.G., Zektzer A.S., Tabatabai Z.L., et al. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med 2006, 55:1257-1264.
18. Serkova N.J., Gamito E.J., Jones R.H., et al. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 2008, 68:620-628.
19. Kline E.E., Treat E.G., Averna T.A., et al. Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection. J Urol 2006, 176:2274-2279.
20. Kamat A.M., Karam J.A., Grossman H.B., et al. Prospective trial to identify optimal bladder cancer surveillance protocol: Reducing costs while maximizing sensitivity. BJU Int 2011 Mar 22, [Epub ahead of print].
21. The use of the bladder-tumor associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. The United Kingdom and Eire Bladder Tumor Antigen Study Group. Br J Urol 1997, 79:362-366.
22. Issaq H.J., Nativ O., Waybright T., et al. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J Urol 2008, 179:2422-2426.
23. Pasikanti K.K., Esuvaranathan K., Ho P.C., et al. Noninvasive urinary metabonomic diagnosis of human bladder cancer. J Proteome Res 2010, 9:2988-2995.
24. Bradamante S., Barchiesi E., Pilotti S., et al. High-resolution 1H NMR spectroscopy in the diagnosis of breast cancer. Magn Reson Med 1988, 8:440-449.
25. Saito K., Kaminaga T., Muto S., et al. Clinical efficacy of proton magnetic resonance spectroscopy (1H-MRS) in the diagnosis of localized prostate cancer. Anticancer Res 2008, 28:1899-1904.
26. Li J.V., Holmes E., Saric J., et al. Metabolic profiling of a Schistosoma mansoni infection in mouse tissues using magic angle spinning-nuclear magnetic resonance spectroscopy. Int J Parasitol 2009, 39:547-558.
27. Srivastava S., Roy R., Singh S., et al. Taurine-a possible fingerprint biomarker in non-muscle-invasive bladder cancer: A pilot study by 1H NMR spectroscopy. Cancer Biomark 2010, 6:11-20.
28. Welsh J.S. Olfactory detection of human bladder cancer by dogs: Another cancer detected by "pet scan,". BMJ 2004, 329:1286-1287.
29. Willis C.M., Church S.M., Guest C.M., et al. Olfactory detection of human bladder cancer by dogs: Proof of principle study. BMJ 2004, 329:712.